Mission Statement

Spencer Technologies is dedicated to saving lives and significantly improving healthcare through the advancement of non-invasive diagnosis, monitoring, and therapy.  It is an integrated patient service, clinical research, R & D, and manufacturing company marketing innovative products and services through worldwide customer relationships.

History

The Company was founded to commercialize technology based on a series of pioneering discoveries by Merrill P. Spencer, M.D., a co-founder and world leader in blood flow diagnosis and monitoring.  In 1987, Dr. Spencer discovered that a non-invasive Doppler ultrasound device could detect particulate blood emboli in real time.  This is the only known method available.  Based on Dr. Spencer’s work, Mark A. Moehring, Ph.D., Director of R & D at Spencer Technologies, formulated a method of counting, sizing and characterizing these emboli as solid or gaseous.  This work is the basis for the Company’s first patent awarded in the United States in 1994 and in Europe in 1997. Since then the Company has applied for 6 additional patents covering its technology.

Unique Philosophy

The Company works in close collaboration with an independent clinical diagnostic laboratory and surgical patient monitoring service in the Seattle area, Spencer Vascular Diagnostic Laboratories.  A guiding principle of the Company is to promote synergy through day-to-day contact between Company engineers and clinicians.  This allows the Company to incorporate the highest level of clinical utility and relevance in its products.

Awards

For more information, please contact:

Spencer Technologies
701 - 16th Avenue
Seattle, WA 98122
1-800-684-0586 (Toll free)
206-329-7220 (local)
206-329-7230 (fax)
info@spencertechnologies.com